Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.
Also called NCT01264692
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 196 participants
- Sponsor
- Idorsia Pharmaceuticals Ltd.
- Registry
-
NCT01264692
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Israel, Serbia
- Registry status
- Completed
Technical summary
Registry record NCT01264692. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Essential Hypertension
- Acronym
- REDUCE-1
- Condition
- Essential Hypertension
- Intervention (Drug)
- ACT-280778
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Amlodipine
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
Record details
- Record id
cardio:ct-nct01264692- Content hash
ac446b4fc8c45e862d2c49926044457bb6a7f866f4dc285445d2582dea920f6d